The Effect of COVID Convalescent Plasma on Hospital Stay: A Retrospective Observational Study from a Tertiary Care Hospital in North India


Cite item

Full Text

Abstract

Introduction:COVID convalescent plasma (CCP) has been used as standard of care in patients all over the world. CCP is plasma collected from recently infected and currently recovered COVID-19 patients, which contains antiviral antibodies that can be used to treat patients with COVID-19. Several studies have shown a shorter hospital stay and lower mortality in patients treated with convalescent plasma in comparison with those not treated with it.

Objectives:This study aims to determine the effect of COVID convalescent plasma (CCP) on the length of hospital stay in symptomatic patients and to determine outcome of the disease in patients who were administered CCP

Methods:This was a retrospective observational study done at a tertiary health care centre from July 2020 to May 2021, including patients who received CCP during the course of their stay in the hospital.

Results:Among 257 participants, the patients with multiple comorbidities who were administered CCP had the longest average length of stay in the hospital which was 15 days, out of which, 92 (35.8%) patients were discharged while 9 (3.5%) patients died. Also, the maximum number of deaths was observed in those patients who had no associated comorbidity, being 11 (4.3%). It was observed that earlier administration of CCP in patients (< 5 days from symptom onset) was associated with a higher number of discharges as compared to deaths.

Conclusion:Our study indicates that CCP may be efficient in treating COVID-19 patients if given in early course of the disease.

About the authors

Prashant Pandey

Transfusion Medicine & Blood centre, Jaypee Hospital

Email: info@benthamscience.net

Shweta Ranjan

Transfusion Medicine & Blood centre, Jaypee Hospital

Email: info@benthamscience.net

Divya Setya

Transfusion Medicine & Blood centre, Jaypee Hospital

Email: info@benthamscience.net

Supriya Kumari

Transfusion Medicine & Blood centre, Jaypee Hospital

Email: info@benthamscience.net

Saikat Mandal

Transfusion Medicine & Blood centre, Jaypee Hospital

Author for correspondence.
Email: info@benthamscience.net

References

  1. Casadevall A, Pirofski L. The convalescent sera option for containing COVID-19. J Clin Invest 2020; 130(4): 1545-8. doi: 10.1172/JCI138003 PMID: 32167489
  2. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment? Ann Intern Med 2006; 145(8): 599-609. doi: 10.7326/0003-4819-145-8-200610170-00139 PMID: 16940336
  3. Lai ST. Treatment of severe acute respiratory syndrome. Eur J Clin Microbiol Infect Dis 2005; 24(9): 583-91. doi: 10.1007/s10096-005-0004-z PMID: 16172857
  4. Soo YOY, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004; 10(7): 676-8. doi: 10.1111/j.1469-0691.2004.00956.x PMID: 15214887
  5. Cheng Y, Wong R, Soo YOY, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24(1): 44-6. doi: 10.1007/s10096-004-1271-9 PMID: 15616839
  6. WHO Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks 2014. http://apps.who.int/iris/rest/bitstreams/604045/retrieve (accessed August 25, 2021)
  7. Arabi Y, Balkhy H, Hajeer AH, et al. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: A study protocol. Springerplus 2015; 4(1): 709. doi: 10.1186/s40064-015-1490-9 PMID: 26618098
  8. Hung IFN, To KKW, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52(4): 447-56. doi: 10.1093/cid/ciq106 PMID: 21248066
  9. Food and Drug Administration. Fact sheet for health care providers: Emergency UseAuthorization (EUA) of COVID-19 convalescent plasma for treatment of coronavirus disease 2019 (COVID-19). 2021. Available at: https://www.fda.gov/media/141478/download
  10. Department of Health and Family Welfare, Ministry of Health and Family Welfare Government of India https://cdsco.gov.in/opencms/opencms/en/Notifications/Gazette-Notifications/ Accessed on 25 Aug 2021.
  11. Rojas M, Rodríguez Y, Monsalve DM, et al. Convalescent plasma in COVID-19: Possible mechanisms of action. Autoimmun Rev 2020; 19(7): 102554. doi: 10.1016/j.autrev.2020.102554 PMID: 32380316
  12. Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 2020; 584(7821): 437-42. doi: 10.1038/s41586-020-2456-9 PMID: 32555388
  13. Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID‐19: Systematic review. J Med Virol 2020; 92(9): 1475-83. doi: 10.1002/jmv.25961 PMID: 32356910
  14. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA 2020; 117(17): 9490-6. doi: 10.1073/pnas.2004168117 PMID: 32253318
  15. Joyner MJ, Senefeld JW, Klassen SA, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: Initial three-month experience. medrxiv 2020; ; 2020-08. doi: 10.1101/2020.08.12.20169359
  16. Zeng QL, Yu ZJ, Gou JJ, et al. Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. J Infect Dis 2020; 222(1): 38-43. doi: 10.1093/infdis/jiaa228 PMID: 32348485
  17. Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection. Chest 2020; 158(1): e9-e13. doi: 10.1016/j.chest.2020.03.039 PMID: 32243945
  18. Budhiraja S, Dewan A, Aggarwal R, et al. Effectiveness of convalescent plasma in Indian patients with COVID-19. Blood Cells Mol Dis 2021; 88: 102548. doi: 10.1016/j.bcmd.2021.102548. Epub2021. PMID: 33621948 PMCID: PMC7891064 doi: 10.2139/ssrn.3726179
  19. Xia X, Li K, Wu L, et al. Improvedclinical symptoms and mortality among patients with severe or critical COVID-19 afterconvalescent plasma transfusion. Blood 2020; 136(6): 755-9. doi: 10.1182/blood.2020007079. PMID: 32573724 PMCID: PMC7414593 doi: 10.1182/blood.2020007079
  20. Libster R, Marc PG, Wappner D, et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. N Engl J Med 2021; 384(7): 610-8. doi: 10.1056/NEJMoa2033700 PMID: 33406353
  21. Abolghasemi H, Eshghi P, Cheraghali AM, et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study. Transfus Apheresis Sci 2020; 59(5): 102875. doi: 10.1016/j.transci.2020.102875 PMID: 32694043
  22. Tang J, Grubbs G, Lee Y, Golding H, Khurana S. Impact of convalescent plasma therapy on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody profile in coronavirus disease 2019 (COVID-19) Patients. Clin Infect Dis 2022; 74(2): 327-34. doi: 10.1093/cid/ciab317 PMID: 33861337

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers